Capivasertib (novel inhibitor): Approved in combination with fulvestrant for patients with HR-positive, HER2-negative breast cancer with a PIK3CA/AKT1/PTEN mutation [90,91,92]. The gene discussed is ERBB2; the disease is breast carcinoma.